Navigation Links
OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
Date:2/11/2009

ROCKVILLE, Md., Feb. 11 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene") today announced it has raised an additional $6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P&A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community. With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins.

Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation. With OriGene's China monoclonal antibody production capacity and these unique genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.

This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.

About OriGene

OriGene Technologies, Inc. is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies for research and drug discovery. Our flagship products are the world's largest cDNA and shRNA clone collections. Other key products include over 100,000 highly validated human tissues through its wholly owned subsidiary Cytomyx LLC., and its tissue derivative products tissue qPCR arrays for biomarker discovery and validation. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher would need for gene based research.

For more information, visit http://www.origene.com/antibody.


'/>"/>
SOURCE OriGene Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
2. New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers
3. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
4. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
5. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
6. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
7. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
8. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
9. Wound Management Technologies, Inc. Announces a Published Case Study
10. Cascades Technologies, Inc. Chosen to Deliver IT Support on a DoD Blast Injury Research Program
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):